Viral Conjunctivitis - Global Pipeline Review, H1 2018


New York, NY -- (SBWIRE) -- 03/08/2018 -- Viral Conjunctivitis


Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031083-viral-conjunctivitis-pipeline-review-h1-2018

Major Key Players:

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Shire Plc

Viral Conjunctivitis Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively.

Viral Conjunctivitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Viral Conjunctivitis - Competitive Analysis

Key players are making innovative developments in Viral Conjunctivitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis.

The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Viral Conjunctivitis therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Viral Conjunctivitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis.


For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031083-viral-conjunctivitis-pipeline-review-h1-2018

About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager



Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)